Prostate Cancer | Specialty

Long-Term Data Show Continued Improved Outcomes for Radiotherapy/Antiandrogen Combination in Locally Advanced Prostate Cancer

January 29th 2014

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%

January 28th 2014

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

Dr. Shore on Genomic Assays in Prostate Cancer

January 27th 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses genomic assays in prostate cancer.

Sequencing Puzzles in CRPC Therapies Remain Unsolved

January 23rd 2014

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Overuse of Bone Scans Demonstrated in Low- and Intermediate-Risk Patients with Prostate Cancer

January 17th 2014

Researchers in the Department of Radiation Oncology at the University of North Carolina Hospitals found that almost one-third of low-risk and almost one-half of intermediate-risk prostate cancer patients received a staging bone scan.

Dr. Mehlhaff on Prostate Cancer Screening Guidelines

January 16th 2014

Bryan A. Mehlhaff, MD, from the Oregon Urology Institute, discusses prostate cancer screening guidelines.

Study: Degarelix Before Leuprolide Can Eliminate Testosterone Surge

December 31st 2013

Patients who undergo androgen deprivation therapy (ADT) to manage advanced prostate cancer will often face the prospect of a potentially dangerous testosterone surge before the downregulation of leuteinizing hormone (LH) secretion occurs and, within about 3 weeks, testosterone drops to castration-like levels.

Hot Flash Treatments That Help Women Fail to Benefit Androgen-Deprived Men

December 20th 2013

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.

Managing Bone Health in Advanced Lung Cancer

December 19th 2013

Managing Bone Health in Breast Cancer

December 19th 2013

Managing Bone Health in Prostate Cancer

December 19th 2013

AR-Targeted Therapies in Advanced Prostate Cancer

December 18th 2013

Multidisciplinary Prostate Cancer Care

December 18th 2013

Radium-223 in CRPC With Bone Metastases

December 18th 2013

Early Detection of Metastatic Prostate Cancer

December 18th 2013

Prechemotherapy Treatment Strategies in CRPC

December 18th 2013

Preventing Skeletal-Related Events in Prostate Cancer

December 18th 2013

Intermittent Versus Continuous ADT in Prostate Cancer

December 18th 2013

LHRH Agonists Versus Antagonists in Prostate Cancer

December 18th 2013

Optimizing ADT in High-Risk Prostate Cancer

December 18th 2013